Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504732 | 0.82 | ALDH1A1 (0.53) | ALDH1A1COMTELANETYR | |
| SCHEMBL19413404 | 0.81 | COMT (0.38) | ALDH1A1COMTELANETYR | |
| SCHEMBL27261485 | 0.78 | TYR (0.41) | ALDH1A1COMTELANEKMT2ATYR | |
| SCHEMBL27261484 | 0.78 | TYR (0.41) | ALDH1A1COMTELANEKMT2ATYR | |
| SCHEMBL27261486 | 0.78 | TYR (0.41) | ALDH1A1COMTELANEKMT2ATYR | |
| SCHEMBL19710679 | 0.73 | PPARG (0.40) | ALDH1A1COMTTYR | |
| SCHEMBL27599241 | 0.72 | ALDH1A1 (0.56) | ALDH1A1SOAT1MAOBKMT2AHSD17B10 | |
| SCHEMBL8687689 | 0.71 | ALDH1A1 (0.67) | ALDH1A1KMT2AKDM4ETSHRLMNA | |
| SCHEMBL1332089 | 0.66 | — | — | |
| SCHEMBL1958756 | 0.66 | ALDH1A1 (1.00) | ALDH1A1SOAT1HSD17B10KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332984-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ALDH1A1 1089/4885COMT 216/4885SOAT1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.